Johnson & Johnson's (JNJ) Multiple Myeloma Breakthrough Drives Buy Rating From Guggenheim

Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim reaffirmed a Buy rating and $206 price target on healthcare giant Johnson & Johnson (NYSE:JNJ), citing favorable clinical trial findings for its multiple myeloma therapy. The firm noted preliminary data from the MajesTEC-3 trial, which combines Johnson & Johnson (NYSE:JNJ)’s Tecvayli and Darzalex medications, as “overwhelmingly positive” and potentially creating a novel standard of treatment for relapsed/refractory multiple myeloma patients.

In comparison to current therapy standard’s, the Tecvayli-Darzalex combination considerably enhanced both progression-free survival and overall survival. Previous Phase 2 data also demonstrated encouraging outcomes, with all evaluable patients achieving a 100% overall response rate with little residual disease negativity.

Guggenheim believes that the data presentation at the upcoming annual American Society of Hematology Meeting in December will highlight a “paradigm shift” in multiple myeloma treatment, potentially boosting Tecvayli’s market share.

Johnson & Johnson (NYSE:JNJ) is a diversified healthcare company. It operates through three main segments: Innovative Medicine, MedTech, and Consumer Health. Its products range from pharmaceuticals and medical devices to widely recognized consumer brands.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.